Genome-wide Specificity of Highly Efficient TALENs and CRISPR/Cas9 for T Cell Receptor Modification

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Friederike Knipping - , Deutsches Krebsforschungszentrum (DKFZ) (Autor:in)
  • Mark J. Osborn - , University of Minnesota System, Asan Medical Center (Autor:in)
  • Karl Petri - , Deutsches Krebsforschungszentrum (DKFZ) (Autor:in)
  • Jakub Tolar - , University of Minnesota System, Asan Medical Center (Autor:in)
  • Hanno Glimm - , Nationales Zentrum für Tumorerkrankungen (NCT) Heidelberg, Deutsches Krebsforschungszentrum (DKFZ) (Autor:in)
  • Christof von Kalle - , Deutsches Krebsforschungszentrum (DKFZ) (Autor:in)
  • Manfred Schmidt - , Deutsches Krebsforschungszentrum (DKFZ) (Autor:in)
  • Richard Gabriel - , Deutsches Krebsforschungszentrum (DKFZ) (Autor:in)

Abstract

In T cells with transgenic high-avidity T cell receptors (TCRs), endogenous and transferred TCR chains compete for surface expression and may pair inappropriately, potentially causing autoimmunity. To knock out endogenous TCR expression, we assembled 12 transcription activator-like effector nucleases (TALENs) and five guide RNAs (gRNAs) from the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas9) system. Using TALEN mRNA, TCR knockout was successful in up to 81% of T cells. Additionally, we were able to verify targeted gene addition of a GFP gene by homology-directed repair at the TALEN target site, using a donor suitable for replacement of the reporter transgene with therapeutic TCR chains. Remarkably, analysis of TALEN and CRISPR/Cas9 specificity using integrase-defective lentiviral vector capture revealed only one off-target site for one of the gRNAs and three off-target sites for both of the TALENs, indicating a high level of specificity. Collectively, our work shows highly efficient and specific nucleases for T cell engineering.

Details

OriginalspracheEnglisch
Seiten (von - bis)213-224
Seitenumfang12
FachzeitschriftMolecular Therapy Methods and Clinical Development
Jahrgang4
PublikationsstatusVeröffentlicht - 17 März 2017
Peer-Review-StatusJa
Extern publiziertJa

Schlagworte

Schlagwörter

  • gene editing, off target, T cell therapy